Citations

Clear

160 citation(s) found for "Wetter, D A".

Autoimmune Bullous Disorders Associated With Immune Checkpoint Inhibitors: A Retrospective Review of a Single Center Cohort Over the Past Decade
Cull, Deborah , Holder, Katherine , Chakraborty, Disha , Bangalore-Kumar, Anagha, Lehman, Julia S , Sominidi Damodaran, Sindhuja

Mayo Clinic

Clinical and Experimental Dermatology | September 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ced/llag427 | PMID 42815983 Get It

Abstract Background Immune checkpoint inhibitors (ICIs) directed against PD-1, PD-L1, and CTLA-4 augment antitumor immune responses but may also induce unintended immune activation, resulting in immune-related adverse events (irAEs). Cutaneous manifestations of irAEs are among the most common, ranging from mild eruptions to severe autoimmune blistering disorders (AIBDs). Although bullous pemphigoid (BP) is the most reported ICI-related autoimmune bullous disorder (irAIBD), data on the spectrum, and management of other ICI-associated AIBDs remain limited. Understanding these reactions is crucial to managing treatment interruptions and influencing oncologic outcomes. Objective This study aims to comprehensively characterize ICI-associated irAIBDs by examining demographics, clinical presentation, disease severity, therapeutic approaches, treatment responses, clinical outcomes, and mortality. Methods A single-institution retrospective chart review was conducted, using a text-based database search from 2011–2023. Adult patients (≥18 years) with biopsy-confirmed AIBDs attributed to ICIs were included. Demographic, oncologic, and immunotherapy details, as well as clinical, histopathologic, and immunofluorescence characteristics of AIBDs, were reviewed. Treatment approaches, outcomes, and mortality data were analyzed. Results Forty-four patients with irAIBDs were identified, predominantly representing males (29, 65.9%) with a mean age of 70.4 years (range: 62-80 years). Lung carcinoma (12, 27.2%) and melanoma (9, 20.4%) were the most frequent underlying malignancies, and pembrolizumab (25, 56.8%) was the most common agent. Bullous pemphigoid (BP) accounted for most cases (36, 81.8%), followed by lichen planus pemphigoides (LPP) (6, 13.6%), with one case each of mucous membrane pemphigoid (MMP) and linear IgA bullous dermatosis (LABD). Pruritus was reported in most (42, 9%) patients, and upper (36, 81.8%), lower (32, 72.2%) extremities and the chest (34, 77.2%) were most often involved. Eosinophilic infiltration was present in most (23, 81.8%) of BP cases, and linear IgG and C3 deposition were the predominant immunofluorescence patterns in BP. Most patients received topical (34, 77.2%) and/or systemic corticosteroids (32, 72.7%), while 16 required at least temporary ICI discontinuation. Four BP (4, 9.1%) patients were treated with dupilumab. Other systemic agents used included doxycycline (22, 50%), intravenous immunoglobulin (IVIG) (5, 11.3%), rituximab (6, 13.6%), dapsone (1, 2.2%), mycophenolate mofetil (1, 2.2%), methotrexate (1, 2.2%), and colchicine (1, 2.2%). Three cases with Grade 3 severity necessitated permanent ICI discontinuation. Clinical stabilization (24, 54.5%) or remission of the irAIBD (16, 36.3%) was achieved in most cases. One death (2.2%) was attributed to sepsis in a patient with severe irAIBD. Conclusion ICI-associated AIBDs are uncommon but clinically significant complications. Most patients in our cohort continued ICI therapy during management of their irAIBD, while others required temporary or permanent interruption. These findings highlight the importance of prompt recognition and multidisciplinary management of these uncommon toxicities.
Anti-p200 pemphigoid: A multi-institutional North American case series of 47 patients with clinical, serologic, and histopathologic data
Agrawal, Shruti , Wanberg, Lindsey J , Camilleri, Michael J, Grover, Raminder, Guerrico, Anatilde González, Shore, Carly J, Culton, Donna, Gonzalez Guerrico, Anatilde, Lehman, Julia S , Camilleri, Michael J., Grover, Raminder, Suresh, Lakshmanan , Culton, Donna Aline , Lehman, Julia S.

Mayo Clinic

British Journal of Dermatology | August 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/bjd/ljag339 | PMID 42608736 Get It

This article describes clinical, serologic, and histopathologic features of the first North American cohort of patients with positive anti-p200 serology identified at Mayo Clinic, Rochester, Minnesota, USA and Beutner Laboratories, Buffalo, New York, USA. Forty-seven patients were identified with positive p200 laminin beta 4 autoantibodies, detected with either immunoglobulin (Ig)G or IgG4 modified indirect immunofluorescence on HEK293 cells transfected with recombinant laminin beta.
Symmetrical drug-related intertriginous and flexural exanthema: Insights from FAERS Database
Le, Duc V, Doan, Nhi H. , Tran, Hue T T, Nguyen, Vinh T H, Wetter, David A. , Nguyen, Giang H, Tran, Hue T.T. , Nguyen, Giang Huong

Mayo Clinic

Clinical and Experimental Dermatology | July 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ced/llag308 | PMID 42500923 Get It

Overall, our findings expand current understanding of SDRIFE by highlighting both well-recognized and underappreciated medication classes, underscoring the importance of ongoing pharmacovigilance.
Facial Discoid Dermatosis: Retrospective Clinical and Immunohistopathologic Cohort Study
Ziebart, Rachel, Newcomer, Jack B. , Chakraborty, Disha , Dacosta, A, Link, Jenny L. , Sominidi‐Damodaran, Sindhuja , Newcomer, Jack , Ziebart, Rachel L , Cull, Deborah B, Chakraborty, Disha , Lehman, Julia S , DaCosta, Adilson , Link, Jenny L , Sominidi Damodaran, Sindhuja , Cull, Deborah , Lehman, Julia S. , DaCosta, Adilson

Mayo Clinic

International Journal of Dermatology | May 23, 2026 | Volume: 65 | Issue: 9 | Pages: 1919-1922

10.1111/ijd.70505 | PMID 42175538 Get It

Drug and Vaccine‐Associated Erythema Nodosum: Insights From the FAERS and VAERS Database
Le, Duc V. , Tran, Tung S. , Tran, Hue T.T. , Wetter, David A. , Nguyen, Giang H., Nguyen, Giang Huong , Nguyen, Giang H , Tran, Tung S

Mayo Clinic

Australasian Journal of Dermatology | May 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/ajd.70140 | PMID 42130103 Get It

Drug Survival of Adalimumab and Infliximab in Hidradenitis Suppurativa
Shrestha, Raslina , Tran, Hue T.T. , Van, Duc L., Wetter, David A. , Nguyen, Giang H., Nguyen, Giang Huong , Nguyen, Giang H

Mayo Clinic

International Journal of Dermatology | May 14, 2026 | Volume: 65 | Issue: 9 | Pages: 1907-1909

10.1111/ijd.70455 | PMID 42129594 Get It

Vitamin D deficiency and systemic inflammation in hidradenitis suppurativa: clinical correlates in a retrospective cohort
Shrestha, Raslina , Van, Duc L., Tran, Hue T T, Ma, Jun, Alavi, Afsaneh, Davis, Mark, Wetter, David A, Lu, Kurt Q. , Nguyen, Giang H, Nguyen, Giang Huong , Tran, Hue T, Nguyen, Giang H , Tran, Hue T.T. , Alavi, Afsáneh , Davis, Mark D.P. , Wetter, David A.

Mayo Clinic

British Journal of Dermatology | April 30, 2026 | Volume: 195 | Issue: 2 | Pages: 339-341

10.1093/bjd/ljag157 | PMID 42056003 Get It

Vitamin D deficiency is frequently reported in hidradenitis suppurativa (HS), but its clinical significance remains unclear. In a retrospective cohort of 503 patients, deficiency was common and associated with demographic and metabolic factors but not with treatment-defined severity. Vitamin D deficiency was independently associated with elevated C-reactive protein, suggesting a link with systemic inflammation.
Cutaneous small-vessel vasculitis with predominant IgM or IgG immune deposits on direct immunofluorescence: What does it mean in clinical practice and how does it fit within the dermatologic addendum to the 2012 revised International Chapel Hill Consensus
Fletcher, Kathleen M., Wetter, David A, Lehman, Julia S. , Wetter, David A. , Lehman, Julia S

Mayo Clinic

Skin Health and Disease | April 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/skinhd/vzag077 | PMID 42812958 Get It

Abstract Cutaneous IgM/IgG immune complex vasculitis is a newly recognized provisional subtype of single-organ vasculitis that is clinically indistinguishable from IgA vasculitis. This retrospective case series evaluated the presence, clinicopathological characteristics and outcomes of patients with IgM and/or IgG dominance or codominance on direct immunofluorescence testing (2010–23). This review represents only the second study to date to characterize this population. Early analysis of 14 patients revealed that cutaneous IgM/IgG immune complex vasculitis was mainly skin limited, and treatment with topical and oral corticosteroids typically resulted in complete resolution without recurrence. Additionally, this study demonstrated that nearly two-thirds (64%) of patients with cutaneous small-vessel vasculitis with IgM and/or IgG dominance or codominance on direct immunofluorescence were ultimately found to have an underlying autoimmune connective tissue disease, cryoglobulinaemia, antineutrophil cytoplasmic antibody-associated vasculitis, infection or a drug-related cause. Therefore, it is imperative that clinicians perform a thorough investigation of this unique population to evaluate for potential underlying diseases and/or triggers.
Recommendations for the diagnostic work‐up of cutaneous small vessel vasculitis – Position Statement of the European Academy of Dermatology and Venereology Vasculitis and Vasculopathy Task Force
Alpsoy, Erkan , Caproni, Marzia , Wetter, David A. , Goebeler, Matthias , Schneider, Stefan W. , Sălăvăstru, Carmen , Llamas‐Velasco, Mar , Akyol, Melih , Dutz, Jan , Jachiet, M. , Kawakami, Tamihiro , Piette, Warren W., Ratzinger, Gudrun , Szepietowski, Jacek C. , Schneider, Stefan W , Llamas-Velasco, Mar , Marzano, Angelo Valerio , Jachiet, Marie , Mariotti, Elena Biancamaria , Maronese, Carlo A , Monfort, Jean-Benoît , Ratzinger, Gudrun , Werth, Victoria P , Szepietowski, Jacek C , Caproni, Marzia , Levell, Nick J. , Maronese, Carlo Alberto , Micheletti, Robert , Werth, Victoria P. , Sunderkötter, Cord

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | December 16, 2025 | Volume: 40 | Issue: 6 | Pages: 946-962

10.1111/jdv.70249 | PMID 41399325 Get It

Abstract Background Small vessel vasculitides (SVV) comprise a heterogeneous group of cutaneous SVV (CSVV) that can be skin‐limited or systemic. Given their diverse forms and symptoms and the lack of a standardized diagnostic approach, it is crucial to establish clear and consensus‐driven recommendations for diagnosis. Objectives To standardize diagnosis for the detection of the type, extent, potential causes or underlying conditions of CSVV. Methods International experts comprised the panel. The Delphi panel data was collected through two rounds of questionnaires. Agreement was measured using an 11‐point Likert scale (0 = strongly disagree, 10 = strongly agree). A 7‐vote minimum was required for agreement on each statement. Delphi panel statements scoring 3–7 were discussed during the meeting. Results 20 experts participated in the first round of the Delphi panel, while 17 experts took part in the second. They agreed that the diagnosis of CSVV relies on a combination of clinical manifestations, laboratory findings and histopathology. Palpable purpura on the lower extremities is recognized as the most reliable hallmark for most SVV and a sign of immune complex vasculitis. When the latter is suspected, a skin biopsy for direct immunofluorescence (DIF) should be obtained from an early, partially blanchable macule because the type of perivascular immunoglobulin is important for further diagnosis. The proper selection of biopsy sites for routine HE biopsy depends on the morphology of lesions. A comprehensive medical history and selected laboratory testing should be conducted to investigate organ involvement, potential causes and associated conditions. The extent of diagnostic procedures should be based on the severity, duration, systemic symptoms and recurrence of SVV. Conclusions Experts reached a strong consensus on the management of CSVV patients, culminating in the first International Consensus Statement for adult CSVV. This statement proposes a practical management algorithm and underscores the importance of collaboration in rare diseases management.
Lichen planus‐like drug eruption: A disproportionality analysis using FAERS database
Tran, Tung S, Le, Duc V. , Nguyen, Trang M , Lehman, Julia S. , Wetter, David A., Nguyen, Giang Huong , Tran, Tung S. , Tran, Tung S , Nguyen, Giang H , Le, Duc V. , Lehman, Julia S , Nguyen, Trang M , Doanh, Le Huu , Wetter, David A.

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | October 30, 2025 | Volume: 40 | Issue: 5 | Pages: No page available

10.1111/jdv.70140 | PMID 41165063 Get It